伊朗2型糖尿病患者的个性化血糖控制:一个多中心数据分析
Abolfazl Sadeghi1, Yahya Bayazidi1, Majid Davari1
1Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Iranian journal of medical sciences
|October 4, 2023
概括
个人化血红蛋白A1c (HbA1c) 目标建议用于2型糖尿病 (T2DM) 患者. 然而,大多数伊朗T2DM患者无法实现这些个性化的血糖目标,导致高并发症率.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 公共卫生 公共卫生
背景情况:
- 临床指南主张在糖尿病管理中使用个性化血红蛋白A1c (HbA1c) 标.
- 关于在伊朗2型糖尿病 (T2DM) 患者中实现个性化血糖目标的数据有限.
- 这项研究通过检查个性化建议的现实世界结果来弥补这一差距.
研究的目的:
- 评估伊朗T2DM患者个性化血糖目标的实现情况.
- 评估与血糖控制有关的微血管和宏血管并发症的发生率.
- 突出这一群体需要个性化的HbA1c策略.
主要方法:
- 在伊朗的15个糖尿病中心 (2013-2017年) 进行了一项横截面研究.
- 1591名T2DM患者使用两阶段集群采样方法被招募.
- 根据Ismail-Beigi的个性化策略,患者被分为五个HbA1c治疗强度组.
主要成果:
- 早期微血管,晚期微血管和宏血管并发症的累积发病率分别为53%,25%和34%.
- 显著的大多数患者 (78%) 无法达到他们个性化的血糖目标.
- 这表明对个性化治疗策略的坚持不佳.
结论:
- 这项研究揭示了伊朗T2DM患者个体化血糖控制不佳.
- 观察到与糖尿病相关并发症的高发病率,与低于最佳的血糖管理有关.
- 实施个性化的HbA1c目标对于改善伊朗T2DM患者的治疗结果至关重要.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes: Management and Pharmacotherapy
302
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
302
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Diabetes: Symptoms, Diagnosis, and Complications
573
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
573


